58,248 Shares in Immunocore Holdings PLC Sponsored ADR $IMCR Bought by Elmind Capital LP

Elmind Capital LP bought a new position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) in the 4th quarter, Holdings Channel.com reports. The firm bought 58,248 shares of the company’s stock, valued at approximately $2,022,000. Immunocore comprises approximately 0.6% of Elmind Capital LP’s holdings, making the stock its 27th biggest holding.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Armistice Capital LLC grew its position in Immunocore by 33.3% in the fourth quarter. Armistice Capital LLC now owns 1,098,000 shares of the company’s stock worth $38,112,000 after acquiring an additional 274,000 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its position in Immunocore by 38.8% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 27,648 shares of the company’s stock worth $960,000 after acquiring an additional 7,726 shares in the last quarter. Cetera Investment Advisers purchased a new position in Immunocore in the fourth quarter worth $203,000. Squarepoint Ops LLC purchased a new position in Immunocore in the fourth quarter worth $534,000. Finally, Eschler Asset Management LLP grew its position in Immunocore by 100.0% in the fourth quarter. Eschler Asset Management LLP now owns 80,000 shares of the company’s stock worth $2,777,000 after acquiring an additional 40,000 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on IMCR shares. Mizuho set a $38.00 target price on shares of Immunocore in a research report on Thursday, February 19th. Needham & Company LLC upped their target price on shares of Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Zacks Research upgraded shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Immunocore currently has an average rating of “Moderate Buy” and a consensus target price of $56.71.

Immunocore Stock Performance

NASDAQ IMCR opened at $28.55 on Thursday. The company has a 50-day simple moving average of $29.45 and a two-hundred day simple moving average of $32.04. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. Immunocore Holdings PLC Sponsored ADR has a 12-month low of $27.56 and a 12-month high of $40.71. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of -51.91 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.51. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The business had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. During the same period in the prior year, the business posted $0.10 earnings per share. The company’s revenue was up 13.6% on a year-over-year basis. On average, equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current year.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.